Signalling pathway alterations in pituitary adenomas: Involvement of Gsα, cAMP and mitogen-activated protein kinases

Journal of Neuroendocrinology

Volumn 21, Issue 11, 2009, Pages 869-877

  Pertuit, M ^a   Barlier, A ^b   Enjalbert, A ^b   Gerard C ^a  

^a University of Mediterranée   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

CAMP; Gs ; MAPK ERK1 2; Pituitary tumourigenesis; Signalling

Indexed keywords

ANGIOPEPTIN; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE 1; OCTREOTIDE; PROTEIN GSALPHA; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; DOWNSTREAM PROCESSING; DRUG RECEPTOR BINDING; GROWTH HORMONE SECRETING ADENOMA; HORMONAL CARCINOGENESIS; HUMAN; HYPOPHYSIS ADENOMA; MOLECULAR INTERACTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ADENOMA; CYCLIC AMP; GROWTH HORMONE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PITUITARY NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 71049194270     PISSN: 09538194     EISSN: 13652826     Source Type: Journal    
DOI: 10.1111/j.1365-2826.2009.01910.x     Document Type: Review

References (94)

1. Shimon I, Melmed S. Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997, 82:1675-1681.
2. Lania A, Mantovani G, Spada A. Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med (Maywood) 2003, 228:1004-1017.
3. Spada A, Lania A, Mantovani G. Hormonal signaling and pituitary adenomas. Neuroendocrinology 2007, 85:101-109.
4. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL. Ras mutations in human pituitary tumors. J Clin Endocrinol Metab 1992, 74:914-919.
5. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, Lu Y. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 2009, 16:301-310.
6. Ballare E, Persani L, Lania AG, Filopanti M, Giammona E, Corbetta S, Mantovani S, Arosio M, Beck-Peccoz P, Faglia G, Spada A. Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 2001, 86:3809-3814.
7. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A, Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. J Clin Endocrinol Metab 2000, 85:781-792.
8. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 2004, 51:227-236.
9. Jaquet P. Evidence for dopamine agonists in the treatment of acromegaly. J Endocrinol 1997, 155(Suppl 1):S59-S60.
10. Pellegrini I, Rasolonjanahary R, Gunz G, Bertrand P, Delivet S, Jedynak CP, Kordon C, Peillon F, Jaquet P, Enjalbert A. Resistance to bromocriptine in prolactinomas. J Clin Endocrinol Metab 1989, 69:500-509.
11. Pellegrini-Bouiller I, Morange-Ramos I, Barlier A, Gunz G, Figarella-Branger D, Cortet-Rudelli C, Grisoli F, Jaquet P, Enjalbert A. Pit-1 gene expression in human lactotroph and somatotroph pituitary adenomas is correlated to D2 receptor gene expression. J Clin Endocrinol Metab 1996, 81:3390-3396.
12. Stefaneanu L, Kovacs K, Horvath E, Buchfelder M, Fahlbusch R, Lancranjan L. Dopamine D2 receptor gene expression in human adenohypophysial adenomas. Endocrine 2001, 14:329-336.
13. Ewing I, Pedder-Smith S, Franchi G, Ruscica M, Emery M, Vax V, Garcia E, Czirjak S, Hanzely Z, Kola B, Korbonits M, Grossman AB. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin Endocrinol (Oxf) 2007, 66:348-352.
14. Musat M, Korbonits M, Kola B, Borboli N, Hanson MR, Nanzer AM, Grigson J, Jordan S, Morris DG, Gueorguiev M, Coculescu M, Basu S, Grossman AB. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr Relat Cancer 2005, 12:423-433.
15. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Duh QY, Clark OH, Kawasaki E, Bourne HR, McCormick F. Two G protein oncogenes in human endocrine tumors. Science 1990, 249:655-659.
16. Spada A, Vallar L, Faglia G. G protein oncogenes in pituitary tumors. Trends Endocrinol Metab 1992, 3:355-360.
17. Buchfelder M, Fahlbusch R, Merz T, Symowski H, Adams EF. Clinical correlates in acromegalic patients with pituitary tumors expressing GSP oncogenes. Pituitary 1999, 1:181-185.
18. Vallar L, Spada A, Giannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987, 330:566-568.
19. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989, 340:692-696.
20. Hamacher C, Brocker M, Adams EF, Lei T, Fahlbusch R, Buchfelder M, Derwahl M. Overexpression of stimulatory G protein alpha-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone. Pituitary 1998, 1:13-23.
21. Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, Enjalbert A, Barlier A. Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int J Cancer 2007, 121:1245-1252.
22. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E, Bosari S, Beck-Peccoz P, Spada A. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res 2004, 64:9193-9198.
23. Ballare E, Mantovani S, Lania A, Di Blasio AM, Vallar L, Spada A. Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors. J Clin Endocrinol Metab 1998, 83:4386-4390.
24. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P, Enjalbert A. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. J Clin Endocrinol Metab 1999, 84:2759-2765.
25. Levis MJ, Bourne HR. Activation of the alpha subunit of Gs in intact cells alters its abundance, rate of degradation, and membrane avidity. J Cell Biol 1992, 119:1297-1307.
26. Naviglio S, Pagano M, Romano M, Sorrentino A, Fusco A, Illiano F, Chiosi E, Spina A, Illiano G. Adenylate cyclase regulation via proteasome-mediated modulation of Galphas levels. Cell Signal 2004, 16:1229-1237.
27. Weinstein LS, Liu J, Sakamoto A, Xie T, Chen M. Minireview: GNAS: normal and abnormal functions. Endocrinology 2004, 145:5459-5464.
28. Weinstein LS, Chen M, Xie T, Liu J. Genetic diseases associated with heterotrimeric G proteins. Trends Pharmacol Sci 2006, 27:260-266.
29. Hayward BE, Barlier A, Korbonits M, Grossman AB, Jacquet P, Enjalbert A, Bonthron DT. Imprinting of the G(s)alpha gene GNAS1 in the pathogenesis of acromegaly. J Clin Invest 2001, 107:R31-R36.
30. Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A. The gsalpha gene: predominant maternal origin of transcription in human thyroid gland and gonads. J Clin Endocrinol Metab 2002, 87:4736-4740.
31. Lynch MJ, Hill EV, Houslay MD. Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling. Curr Top Dev Biol 2006, 75:225-259.
32. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther 2006, 109:366-398.
33. Lania A, Persani L, Ballare E, Mantovani S, Losa M, Spada A. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab 1998, 83:1624-1628.
34. Persani L, Borgato S, Lania A, Filopanti M, Mantovani G, Conti M, Spada A. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(alpha) mutations. J Clin Endocrinol Metab 2001, 86:3795-3800.
35. Peri A, Conforti B, Baglioni-Peri S, Luciani P, Cioppi F, Buci L, Corbetta S, Ballare E, Serio M, Spada A. Expression of cyclic adenosine 3′,5′-monophosphate (cAMP)-responsive element binding protein and inducible-cAMP early repressor genes in growth hormone-secreting pituitary adenomas with or without mutations of the Gsalpha gene. J Clin Endocrinol Metab 2001, 86:2111-2117.
36. Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 1995, 9:777-783.
37. Ham J, Ivan M, Wynford-Thomas D, Scanlon MF. GH3 cells expressing constitutively active Gs alpha (Q227L) show enhanced hormone secretion and proliferation. Mol Cell Endocrinol 1997, 127:41-47.
38. Kim E, Sohn S, Lee M, Park C, Jung J, Park S. Effect of gsp oncogene on somatostatin receptor subtype 1 and 2 mRNA levels in GHRH-responsive GH3 cells. Pituitary 2005, 8:155-162.
39. Yang X, Lee FY, Wand GS. Increased expression of Gs(alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997, 11:1053-1061.
40. Gaiddon C, Mercken L, Bancroft C, Loeffler JP. Transcriptional effects in GH3 cells of Gs alpha mutants associated with human pituitary tumors: stimulation of adenosine 3′,5′-monophosphate response element-binding protein-mediated transcription and of prolactin and growth hormone promoter activity via protein kinase A. Endocrinology 1995, 136:4331-4338.
41. Romano D, Magalon K, Pertuit M, Rasolonjanahary R, Barlier A, Enjalbert A, Gerard C. Conditional overexpression of the wild-type Gs alpha as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines. Endocrinology 2007, 148:2973-2983.
42. Goldsmith ZG, Dhanasekaran DN. G protein regulation of MAPK networks. Oncogene 2007, 26:3122-3142.
43. Gerits N, Kostenko S, Shiryaev A, Johannessen M, Moens U. Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 2008, 20:1592-1607.
44. Houslay MD, Kolch W. Cell-type specific integration of cross-talk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 2000, 58:659-668.
45. Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 2002, 12:258-266.
46. Dumaz N, Marais R. Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 2005, 272:3491-3504.
47. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, Chen W, Cobb MH. The roles of MAPKs in disease. Cell Res 2008, 18:436-442.
48. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007, 26:3279-3290.
49. Lania A, Filopanti M, Corbetta S, Losa M, Ballare E, Beck-Peccoz P, Spada A. Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. J Clin Endocrinol Metab 2003, 88:1692-1696.
50. Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P, Spada A, Lania AG. Effect of cyclic adenosine 3′,5′-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 2005, 90:6721-6724.
51. Robinson-White A, Hundley TR, Shiferaw M, Bertherat J, Sandrini F, Stratakis CA. Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet 2003, 12:1475-1484.
52. Wang YH, Maurer RA. A role for the mitogen-activated protein kinase in mediating the ability of thyrotropin-releasing hormone to stimulate the prolactin promoter. Mol Endocrinol 1999, 13:1094-1104.
53. Le Pechon-Vallee C, Magalon K, Rasolonjanahary R, Enjalbert A, Gerard C. Vasoactive intestinal polypeptide and pituitary adenylate cyclase- activating polypeptides stimulate mitogen-activated protein kinase in the pituitary cell line GH4C1 by a 3′,5′-cyclic adenosine monophosphate pathway. Neuroendocrinology 2000, 72:46-56.
54. Wang YH, Jue SF, Maurer RA. Thyrotropin-releasing hormone stimulates phosphorylation of the epidermal growth factor receptor in GH3 pituitary cells. Mol Endocrinol 2000, 14:1328-1337.
55. Kievit P, Lauten JD, Maurer RA. Analysis of the role of the mitogen-activated protein kinase in mediating cyclic-adenosine 3′,5′-monophosphate effects on prolactin promoter activity. Mol Endocrinol 2001, 15(4):614-624.
56. Yonehara T, Kanasaki H, Yamamoto H, Fukunaga K, Miyazaki K, Miyamoto E. Involvement of mitogen-activated protein kinase in cyclic adenosine 3′,5′-monophosphate-induced hormone gene expression in rat pituitary GH(3) cells. Endocrinology 2001, 142:2811-2819.
57. Kanasaki H, Yonehara T, Yamamoto H, Takeuchi Y, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E. Differential regulation of pituitary hormone secretion and gene expression by thyrotropin-releasing hormone. A role for mitogen-activated protein kinase signaling cascade in rat pituitary GH3 cells. Biol Reprod 2002, 67:107-113.
58. Pickett CA, Gutierrez-Hartmann A. Ras mediates Src but not epidermal growth factor-receptor tyrosine kinase signaling pathways in GH4 neuroendocrine cells. Proc Natl Acad Sci USA 1994, 91:8612-8616.
59. Castillo AI, Tolon RM, Aranda A. Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3-kinase dependent mechanism. Oncogene 1998, 16:1981-1991.
60. Romano D, Pertuit M, Rasolonjanahary R, Barnier JV, Magalon K, Enjalbert A, Gerard C. Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells. Endocrinology 2006, 147:6036-6045.
61. Romano D, Magalon K, Ciampini A, Talet C, Enjalbert A, Gerard C. Differential involvement of the Ras and Rap1 small GTPases in vasoactive intestinal and pituitary adenylyl cyclase activating polypeptides control of the prolactin gene. J Biol Chem 2003, 278:51386-51394.
62. Spada A, Arosio M, Bochicchio D, Bazzoni N, Vallar L, Bassetti M, Faglia G. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J Clin Endocrinol Metab 1990, 716:1421-1426.
63. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P. Pronostic and therapeutic consequences of Gs alpha mutations in somatotroph adenomas. J Clin Endocrinol Metab 1998, 83:1604-1610.
64. Taboada GF, Tabet AL, Naves LA, De Carvalho DP, Gadelha MR. Prevalence of gsp oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience. Pituitary 2009, 12:165-169.
65. Tian J, Chen J, Bancroft C. Expression of constitutively active Gs alpha-subunits in GH3 pituitary cells stimulates prolactin promoter activity. J Biol Chem 1994, 269:33-36.
66. Gaiddon C, Tian J, Loeffler JP, Bancroft C. Constitutively active G(S) alpha-subunits stimulate Pit-1 promoter activity via a protein kinase A-mediated pathway acting through deoxyribonucleic acid binding sites both for Pit-1 and for adenosine 3′,5′-monophosphate response element-binding protein. Endocrinology 1996, 137:1286-1291.
67. Billestrup N, Swanson LW, Vale W. Growth hormone-releasing factor stimulates proliferation of somatotrophs in vitro. Proc Natl Acad Sci USA 1986, 83:6854-6857.
68. Chien J, Wong E, Nikes E, Noble MJ, Pantazis CG, Shah GV. Constitutive activation of stimulatory guanine nucleotide binding protein (G(S)alphaQL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells. Oncogene 1999, 18:3376-3382.
69. Santore TA, Chen Y, Smit MJ, Iyengar R. Adenovirus-directed expression of Q227L-G alpha(s) inhibits growth of established tumors of later-stage human breast cancer cells in athymic mice. Proc Natl Acad Sci USA 2002, 99:1671-1676.
70. Bevan JS. Clinical review: the antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 2005, 90:1856-1863.
71. Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, Vance ML, Rhew D, Kleinberg D, Barkan A. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab 2005, 90:4405-4410.
72. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, Doneda P, Cortesi L, Pagani G. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006, 91:1397-1403.
73. Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, Caranci F, Cirillo S, Lombardi G. Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab 2006, 91:2112-2118.
74. Danila DC, Haidar JN, Zhang X, Katznelson L, Culler MD, Klibanski A. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors. J Clin Endocrinol Metab 2001, 86:2976-2981.
75. Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, Jaquet P, Culler MD, Bianchi F, Rebora A, Minuto F, Ferone D. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab 2007, 92:1592-1599.
76. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J, Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clin Endocrinol (Oxf) 2008, 68:458-465.
77. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, Culler MD, Moreau JP, Enjalbert A, Jaquet P. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001, 86:140-145.
78. Ferrante E, Pellegrini C, Bondioni S, Peverelli E, Locatelli M, Gelmini P, Luciani P, Peri A, Mantovani G, Bosari S, Beck-Peccoz P, Spada A, Lania A. Octreotide promotes apoptosis in human somatotroph tumor cells by activating somatostatin receptor type 2. Endocr Relat Cancer 2006, 13:955-962.
79. Acunzo J, Thirion S, Roche C, Saveanu A, Gunz G, Germanetti AL, Couderc B, Cohen R, Figarella-Branger D, Dufour H, Brue T, Enjalbert A, Barlier A. Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res 2008, 68:10163-10170.
80. Ezzat S, Kontogeorgos G, Redelmeier DA, Horvath E, Harris AG, Kovacs K. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 1995, 133:686-690.
81. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005, 90:6290-6295.
82. Corbetta S, Ballare E, Mantovani G, Lania A, Losa M, Di Blasio AM, Spada A. Somatostatin receptor subtype 2 and 5 in human GH-secreting pituitary adenomas: analysis of gene sequence and mRNA expression. Eur J Clin Invest 2001, 31:208-214.
83. Enjalbert A, Bertrand P, Bockaert J, Drouva S, Kordon C. Multiple coupling of neurohormone receptors with cyclic AMP and inositol phosphate production in anterior pituitary cells. Biochimie 1987, 69:271-279.
84. Epelbaum J, Enjalbert A, Krantic S, Musset F, Bertrand P, Rasolonjanahary R, Shu C, Kordon C. Somatostatin receptors on pituitary somatotrophs, thyrotrophs, and lactotrophs: pharmacological evidence for loose coupling to adenylate cyclase. Endocrinology 1987, 121:2177-2185.
85. Musset F, Bertrand P, Kordon C, Enjalbert A. Differential coupling with pertussis toxin-sensitive G proteins of dopamine and somatostatin receptors involved in regulation of adenohypophyseal secretion. Mol Cell Endocrinol 1990, 73:1-10.
86. Tentler JJ, Hadcock JR, Gutierrez-Hartmann A. Somatostatin acts by inhibiting the cyclic 3′,5′-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency. Mol Endocrinol 1997, 11:859-866.
87. Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 2008, 13:822-840.
88. Florio T, Yao H, Carey KD, Dillon TJ, Stork PJ. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). Mol Endocrinol 1999, 13:24-37.
89. Ferjoux G, Lopez F, Esteve JP, Ferrand A, Vivier E, Vely F, Saint-Laurent N, Pradayrol L, Buscail L, Susini C. Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation. Mol Biol Cell 2003, 14:3911-3928.
90. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S, Susini C. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003, 278:39356-39371.
91. Arena S, Pattarozzi A, Massa A, Esteve JP, Iuliano R, Fusco A, Susini C, Florio T. An intracellular multi-effector complex mediates somatostatin receptor 1 activation of phospho-tyrosine phosphatase eta. Mol Endocrinol 2007, 21:229-246.
92. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, Papotti M, Terreni MR, Khalaf S, Jordan S, Czirjak S, Hanzely Z, Nagy GM, Goth MI, Grossman AB, Korbonits M. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol 2006, 155:371-379.
93. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U, Stalla GK. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Res 2006, 66:1576-1582.
94. Theodoropoulou M, Tichomirowa MA, Sievers C, Yassouridis A, Arzberger T, Hougrand O, Deprez M, Daly AF, Petrossians P, Pagotto U, Beckers A, Stalla GK. Tumor ZAC1 expression is associated with the response to somatostatin analog therapy in patients with acromegaly. Int J Cancer 2009, 125:2122-2126.